Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00510497Phase 1Completed

Autologous Dendritic Cell Vaccine in HIV1 Infection

Role: lead

NCT03758625Phase 1Completed

Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure

Role: lead

NCT02121756Phase 1Completed

Dipyridamole for Immune Activation in HIV

Role: lead

All 3 trials loaded